These findings suggest that IKK/NF-κB signaling could provide a promising therapeutic target in SCLC and warrant further studies experimentally assessing the effect of NF-κB pathway inhibition on established SCLC. The gene discussed is NFKB1; the disease is small cell lung carcinoma.